Introduction
Multiple sclerosis is a chronic inflammatory disease of the CNS (Noseworthy et al., 2000) . The importance of axonal damage as a denominator of persistent disability re-entered the focus of interest (Trapp et al., 1998) , not only in the chronic disease phase but already early and in acute multiple sclerosis lesions (Kuhlmann et al., 2002) . In particular, axonal loss may correlate with neurological impairment (Wujek et al., 2002) , which is corroborated by in vivo magnetic resonance imaging with detection of brain atrophy as well as by magnetic resonance spectroscopy with a decrease of the neuronal marker N-acetyl aspartate in multiple sclerosis brain (Narayanan et al., 1997) . Although several autoaggressive mechanisms for axonal degeneration are well characterized (Coleman et al., 2002; Stys, 2004) , only a few protective pathways have been described in experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (Gold et al., 2006) . Besides a mutation in the ubiquitin-proteasome pathway in the natural occurring ola/wld S mouse-mutant (Chitnis et al., 2007) , the neurotrophic cytokine ciliary neurotrophic factor was shown to play a major protective role in myelin oligodendrocyte glycoprotein (MOG)-induced EAE (hereafter MOG-EAE) . Further candidates for axon protection include neurotrophins, amongst them brain-derived neurotrophic factor (BDNF), which mediates numerous effects on neurons via receptor tyrosine kinases (Chao, 2003) . Physiological functions include axonal growth, modulation of neuronal activity, activity-dependent synaptic and dendritic plasticity or impact on memory and learning (Hohlfeld et al., 2000; Sendtner et al., 2000; Markus et al., 2002) . Additionally, BDNF can also be important under pathological conditions like pain, aggression, depression or substance abuse (Angelucci et al., 2005) . In the CNS, neurons are the main source of BDNF (Hofer et al., 1988; Lewin et al., 1996) . Another potential source are activated astrocytes, which are present in inflamed areas in the CNS as shown in EAE, multiple sclerosis and also Alzheimer's disease (Stadelmann et al., 2002; Burbach et al., 2004) . The expression of neurotrophins and their respective receptors has also been detected in lymphoid organs such as thymus and spleen (Timmusk et al., 1993; Laurenzi et al., 1994; Kruse et al., 2007) . Moreover, activated T cells, B cells and monocytes express bioactive BDNF in vitro and in multiple sclerosis or EAE lesions (Kerschensteiner et al., 1999; Stadelmann et al., 2002) . In human and murine T cells, BDNF production can be increased by treatment with glatiramer acetate (Ziemssen et al., 2002; Aharoni et al., 2003) , a well established disease-modifying drug in multiple sclerosis that therapeutically modulates antigen-presenting cells (Weber et al., 2007) and may also possess a neuroprotective capacity (Aharoni et al., 2005) . However, the functional role of BDNF in the immune system is not yet clear. Previous studies indicated a role of BDNF in survival and activation of eosinophilic granulocytes (Nassenstein et al., 2003) , as well as during B cell development (Schuhmann et al., 2005) . The observation of BDNF production by immune cells in the injured nervous system lends credence to the concept of neuroprotective (auto)immunity (Schwartz et al., 2001 ). However, a definitive proof of this hypothesis has been difficult since conventional BDNF knockout mice die soon after birth (Korte et al., 1995) .
Here we employ conditional BDNF knockout mice as well as lentiviral overexpression of BDNF in T cells to investigate the function of BDNF in MOG-EAE in the C57BL/6 mouse, a model mimicking many inflammatory and neurodegenerative aspects of multiple sclerosis (Herrero-Herranz et al., 2008) . Our data reveal a pivotal role for BDNF in axon protection during chronic autoimmune demyelination of the CNS, which can be therapeutically modulated by glatiramer acetate.
Materials and methods
Mice C57BL/6 mice were purchased from Harlan (Borchen, Germany) and bred at the in-house animal care facilities of the Institute for Multiple Sclerosis Research, University of Gö ttingen, Germany. All animal experiments were performed in accordance with the Bavarian and Lower Saxony State regulations for animal welfare. Transgenic 2D2 mice harbouring a MOG 35-55-specific T-cell receptor were kindly provided by V.K. Kuchroo, Boston, USA (Bettelli et al., 2003) and green fluorescent protein transgenic mice were obtained from the Jackson Laboratories (stock number 003291; Bar Harbor, ME, USA). Conditional BDNF fl/fl mice were generated by the introduction of two loxP sites flanking the coding exon 8 (Matsumoto et al., 2008) . These mice were crossed with mice expressing Cre under the control of the proximal lck promoter (Hennet et al., 1995) (stock number 006889; Jackson Laboratories), the lysMCre promoter specific for myeloid cells (Clausen et al., 1999) (kindly provided by Dr. Irmgard Fö rster from the Institute for Molecular Preventive Medicine, University of Dü sseldorf, Germany) or the glial fibrillary acidic protein Cre promoter (kindly provided by Silvia Marino from the Department of Pathology, Zurich, Switzerland) that leads to conditional gene deletion in astrocytes and some neuronal subpopulations (Marino et al., 2000) . All mice were backcrossed to the C57BL/6 background for more than 10 generations. For all genotypes, age-and gender-matched littermate controls were used. Wild-type control mice were only employed if first experiments with direct comparison to littermate controls did not indicate any differences.
Induction and clinical evaluation of active MOG-EAE and glatiramer acetate therapy
For active induction of MOG-EAE, mice received a subcutaneous injection at the flank and tail base of 200 mg MOG 35-55 peptide (Institute of Medical Immunology, Charité , Berlin, Germany) in phosphate-buffered saline emulsified in an equal volume of complete Freund's adjuvant containing Mycobacterium tuberculosis H37RA (Difco, Detroit MI, USA) at a final concentration of 1 mg/ml. Two injections of pertussis toxin (List Biochemicals, Campbell, CA, USA, 400 ng per mouse i.p.) were given at the time of immunization and 48 h later. Glatiramer acetate was applied by co-immunization with MOG at a dose of 500 mg. Animals were weighed and scored for clinical signs of disease in a blinded manner on a daily basis using a clinical score as described previously . When mice had to be euthanized for ethical reasons, they were scored as '10' on the day subsequent to their death. Data are presented as mean + SEM.
Histochemistry and immunohistochemistry
Spinal cord cross-sections were subjected to haematoxylin/eosin staining to assess inflammation, luxol fast blue for demyelination and Bielschowsky silver impregnation to investigate axonal densities. Immunohistochemistry was performed with 3 mm paraffin sections as described . T cells were labelled by rat anti-CD3 (Serotec; Wiesbaden, Germany; 1:300) and macrophages/microglia by rat anti-mouse Mac-3 (Becton Dickinson Pharmingen, Heidelberg, Germany; 1:200). Phosphorylated TrkB was labelled with a rabbit anti-phosphorylated TrkB antibody (1 : 50, kind gift from Moses Chao, New York University, USA), inducible nitric oxide synthase with an anti-inducible nitric oxide synthase antibody (1:100, Abcam, Cambridge, UK), BDNF with a rabbit anti-BDNF antibody (1 : 100; Millipore, Hofheim, Germany), neurons with a mouse anti-NeuN antibody (1:200, Millipore) and astrocytes with a rabbit anti-glial fibrillary acidic protein antibody (1:1000; DAKO, Hamburg, Germany). Axonal damage was assessed by amyloid precursor protein (APP) staining (1 : 1000, MAB348, Millipore) or the neurofilament antibodies SMI31 and SMI32 (Invitrogen, Karlsruhe, Germany 1 : 1000) with anti-mouse Alexa 488-and Alexa 647-conjugated secondary antibodies. APP-positive profiles were counted in lesions as defined by the loss of myelin and inflammatory infiltration.
Lentiviral brain-derived neurotrophic factor construct
Lentiviral vectors of the third generation (pLenti6/V5, Invitrogen, Karlsruhe, Germany) were used for transduction of human embryonic kidney cells and MOG transgenic T cells. The cytomegalovirus promoter was replaced by a phosphoglycerate kinase promoter and either the green fluorescent protein or the BDNF gene was subcloned downstream. The correct nature of all cloned sequences was confirmed by automated sequencing (Eurofins MWG, Martinsried, Germany). Generation of lentiviral particles were performed as described by Follenzi et al. (2002) . In brief, modified pLenti6/V5 vectors were purified and then cotransfected together with packaging vectors (Invitrogen) into 293T cells. The supernatant was collected after 48 h, and viral particles in the supernatant were concentrated by ultracentrifugation at 50 000g for 2 h and recovered by suspension in phosphate-buffered saline.
Lentiviral infection of human embryonic kidney cells and MOG transgenic T cells and injection protocol
Lentiviral particles and 10 mg/ml Polybrene (Sigma-Aldrich, Munich, Germany) were added to MOG transgenic T cells ($1 Mio cells/ml) and cultured for 1 h at 37 C in ex vivo medium (Cambrex Bio Science, Verviers, Belgium). T cells were then collected with the supernatant and centrifuged for 90 min at 813 g and 32 C (11650 rotor; Sigma). )-sorted splenocytes after intravenous injection and in vivo expansion for 4-6 days. Green fluorescent protein expression was monitored by fluorescence microscopy or fluorescenceactivated cell-sorting analysis.
Fluorescence-activated cell-sorting analyses
Isolation of spinal cord infiltrates was performed as described previously (Wust et al., 2008) . The following antibodies were used for analysis: anti-mouse CD4 (clone GK 1.5), anti-mouse CD25 (clone 7D4) and anti-mouse CD44 (clone IM7, all from Becton Dickinson Heidelberg, Germany). For intracellular staining, the FoxP3 staining kit (clone FJK-16s) from eBioscience (San Diego, CA, USA) was employed according to the manufacturer instructions. Single-cell suspensions (300 000 cells) from individual organs were stained for 15 min on ice in the dark and washed with fluorescence-activated cell-sorting buffer (phosphate-buffered saline/2% bovine serum albumin/0.1% NaN 3 ). If the first antibody was biotinylated, a second staining step with labelled streptavidin was performed for 15 min also followed by a washing step with fluorescence-activated cell-sorting buffer. Analysis was performed by four-colour flow cytometry using a FACSCalibur and FacScan software (BD).
Proliferation assay
For spleen-cell proliferation assays, single-cell suspensions of spleen from MOG 35-55 immunized lysMCre lckCre BDNF fl/fl (LLF) mice and control mice were prepared 9 days after immunization of mice with 200 mg MOG 35-55 . 2 Â 10 5 cells were seeded in 96-well microtitre plates (Nunc, Wiesbaden, Germany) in 100 ml medium with the addition of antigen or mitogen. Concentrations were 20 mg/ml for MOG and 1.25 mg/ml for ConA. Triplicate cultures were maintained at 37 C in a humidified atmosphere with 5% CO 2 for 56 h and harvested following a 16 h pulse with 0.2 mCi/well 3 H-dT (tritiated thymidine, Amersham-Buchler, Braunschweig, Germany). Cells were collected on fibreglass filter paper with a 96-well harvester (Pharmacia, Freiburg, Germany), and radioactivity was measured with a 96-well Betaplate liquid scintillation counter (Pharmacia).
Enzyme-linked immunosorbent assay
Splenocytes were prepared and cultured as above with media alone or in the presence of 20 mg/ml of MOG 35-55 peptide or 1.25 mg/ml ConA. Astrocytes were cultured with media alone or in the presence of 100 U/ml interferon-. Supernantants were harvested after 3 days of culture. Interferon-, interleukin-17 or interleukin-6 concentrations were determined by sandwich enzyme-linked immunosorbent assay, as described (Crowther, 1995) . Monoclonal antibody pairs and recombinant cytokine standards were purchased from BD for all cytokines. In some assays, T cells were isolated by MACS TM (Miltenyi, Bergisch-Gladbach, Germany) and co-cultured with freshly prepared antigen-presenting cells from spleen of wild-type or LLF donors.
Reverse transcriptase-polymerase chain reaction protocol
Total RNA from brain, freshly prepared T cells (purified via magnetic beads, Miltenyi), peritoneal macrophages (prepared as described in Linker et al., 2008) , microglia or astrocytes [prepared as described in Magnus et al. (2002) and Takahashi et al. (2007) ] was purified over RNeasy columns (Qiagen, Hilden, Germany) . Reverse transcription was performed with 12 ml of purified RNA with 200 U Superscript II reverse transcriptase. Quantification of beta-actin was achieved with primers
was measured with mBDNF3 S (5 0 -GGGCCGGATGCTTCCTT-3 0 ), mBDNF3 AS (5 0 -GCAACCGAAGTATGAAATAACCATAG-3 0 ), and mBDNF Son (5 0 -TTCCACCAGGTGAGAAGAGTGATGACCAT-3 0 ) as primers, whereas the BDNF coding sequence was amplified with the primers mBDNFs (5 0 -ACTTGGCCTACCCAGGTGTG-3 0 ) and mBDNFas (5 0 -GCATCACCCGGGAAGTGTAC-3 0 ), using the Sybr green method.
All PCR reactions were performed on a 7500 Real Time PCR System (Applied Biosystems) in quadruplicates; relative quantification was performed according to Livak and Schmittgen (Livak et al., 2001 ).
Murine and chicken dorsal root ganglion cell survival assay
Embryonic Day 12.5 mouse dorsal root ganglion or embryonic Day 9 chick dorsal root ganglion neurons were isolated as described previously (Wiese et al., 1999 (Wiese et al., , 2001 ). In brief, dorsal root ganglia were isolated and treated with trypsin (0.1% final concentration; Worthington, USA) for 30 min at 37 C. The digestion was stopped with the serum-containing medium (Dulbecco's modiEed Eagle's medium, 10% horse serum), plated on a 10 cm Falcon cell culture dish and incubated for 4 h at 37 C in the incubator (humidified atmosphere, 5% CO 2 ). The cell suspension was taken from the plate, counted and plated on Greiner 4-well culture dishes at a density of 3000 cells/well. Neurotrophic factors (BDNF at 10 ng/ml, 1 ng/ml and 0.1 ng/ml) were added 1 h after plating. Initial counting of plated cells was performed when all cells were attached to the culture dish after 4 h. Phase bright cells were counted at Day 1. Five visual fields (1.9 mm 2 /field) were counted in each well at each time point in a blinded manner to experimental conditions.
Microscopy and data analysis
Spinal cord cross-sections were analysed by a blinded investigator using light microscopy (Olympus, Hamburg, Germany). Blinded quantification of axons and immune cells was performed on serial sections and included six independent spinal cord cross-sections per mouse. Immune cells were counted by means of overlaying a stereological grid onto sections and counting inflammatory infiltrates per mm 2 white matter. Quantification of areas affected by myelin loss on luxol fast blue or CNPase-stained sections was performed semiautomatically with the help of CellD Software (Olympus). Areas with complete myelin loss and homogeneous immune cell infiltration were identified as lesion, the adjacent tissue with sparse myelin loss and scattered immune cells as perilesional area and areas of the adjacent tracts as normal appearing white matter on spinal cord cross-sections of cervical, thoracic and lumbar spinal cord (Herrero-Herranz et al., 2008) . On the same sections, axonal densities in grey matter were quantified on defined areas from the lateral anterior horn and medial dorsal horn. For quantification of axons on spinal cord cross-sections, silver impregnated profiles were counted on six visual fields involving cervical, thoracic and lumbar spinal cord using a grid of 100 mm diameter [modified from Mews et al. (1998) and Bitsch et al. (2000) ]. Data are presented as relative axonal densities.
Western blot
The dissected spinal cord was homogenized in 10 volumes of 100 mM phosphate buffer containing 1 mM EDTA, 2 M guanidine hydrochloride (pH 7.2) and three protease inhibitors, namely 10 mM N-ethylmaleimide, 0.36 mM pepstatin and 1 mM phenylmethylsulphonyl fluoride.
Homogenates were sonicated and centrifuged at 46 000g for 30 min at 4 C. For sodium dodecyl sulphate polyacrylamide gel electrophoresis, protein samples were incubated for 15 min at 95 C in a sample buffer (Invitrogen, Karlsruhe, Germany). After sodium dodecyl sulphate polyacrylamide gel electrophoresis, the protein was electrophoretically transferred to nitrocellulose membranes by semidry blotting. The nitrocellulose membranes were blocked for 1 h at 25 C in a blocking buffer including 3% skimmed milk powder. For antibody reaction, the blots were incubated for 48 h at 4 C with a polyclonal rabbit antibody against BDNF (1:100, Millipore) or b-actin (1:400, Millipore). Blots were then washed with the blocking buffer, and bound label was visualized by enhanced chemiluminescence (Supersignal West Femto Kit, Thermo Scientific, Bonn, Germany).
Statistical analysis
Statistical analyses of clinical course and histological data were performed by the Mann-Whitney U-test for two groups or the KruskalWallis test for four groups (PRISM software, Graph Pad, San Diego, CA, USA). A t-test was employed to analyse reverse transcriptase polymerase chain reaction data. P-values were considered significant at *P50.05, **P50.01, ***P50.001. All error bars represent SEM.
Results

Regulation of BDNF and its activated receptor-phosphorylated TrkB during autoimmune demyelination
BDNF is considered to play a neuroprotective and survivalstimulating role in the CNS. At first therefore we compared the expression of BDNF in the spinal cord of naive C57BL/6 mice with mice immunized with MOG 35-55. On Day 14 post-injection (p.i.), there was a significant reduction of BDNF mRNA expression (whole coding sequence BDNF as well as BDNF3 splice variant) in the diseased spinal cord ( Fig. 1A and data not shown). At the histological level, induction of EAE led to up-regulation of BDNF in astrocytes ( Fig. 1B and C) , down-regulation in NeuN expressing cells ( Fig. 1D and E), as well as loss of BDNF positive axons ( Fig. 1F and G) . In contrast, expression of the activated BDNF receptor phosphorylated TrkB, which indicates binding of BDNF to its high-affinity receptor, was up-regulated in neurons of EAE-diseased mice ( Fig. 1H and I ). On intact axons, phosphorylated TrkB was not readily found (data not shown). Yet, patchy phosphorylated TrkB expression was detected in EAE lesions on axons positive for non-phosphorylated neurofilaments (Fig. 1J) . In summary, the expression of BDNF and its receptor TrkB is regulated under neuroinflammatory conditions.
Endogenous CNS-derived BDNF is axon protective in MOG-EAE
To test for the functional relevance of BDNF signalling in autoimmune demyelination, we studied neuroinflammation in the setting of absent or significantly reduced BDNF expression. Since conventional BDNF knockout mice (BDNF À/À mice) die soon after birth (Korte et al., 1995) , we used the Cre-loxP system including BDNF fl/fl mice (Matsumoto et al., 2008) to generate mice with a conditional deficiency of BDNF in different cell types. As a proof of principle, we first investigated the axon-protective role of BDNF in a knockout model affecting cells in the CNS. To this end, we generated glial fibrillary acidic protein Cre BDNF fl/fl (GfapF) mice in which Cre-mediated recombination occurs in astroglia and also in some neuronal subpopulations (Marino et al.,2000) . GfapF mice display a mild motor hyperactivity, but do not show any gross neurologic phenotype (data not shown). As revealed by reverse transcriptase polymerase chain reaction analysis, GfapF mice express BDNF mRNA levels below 25% of control mice in cultured primary astrocytes, resulting in a more than 75% reduction of BDNF mRNA expression. In contrast, there was no difference in BDNF expression in cultured microglia from both genotypes thus proving the tissue specificity of the knockout ( Fig. 2A) . Analysis of cytokine patterns in culture supernatants from naive or interferon--stimulated astrocytes did not show any difference in interleukin-6 production as compared to littermate controls (Fig. 2B) . Similar results were obtained for the production of tumour necrosis factor-(data not shown). At the histological level, astrocytes in the inflamed spinal cord of GfapF mice were BDNF-negative while BDNF expression was readily detected in grey matter astrocytes of wild-type controls. In contrast, there was no difference in neuronal BDNF expression between GfapF and wild-type mice ( Supplementary Fig. 1A , C, D and F). In comparison to littermate BDNF fl/fl mice, the course of MOG-EAE in GfapF mice was more severe. At the maximum of disease, GfapF mice suffered from severe paraparesis while control mice only displayed gait ataxia (Fig. 2C) . At the same time, mortality in GfapF mice was increased (mortality: 0/7 BDNF fl/fl mice versus 3/16 GfapF mice, P = 0.01) while disease onset and incidence were not different. On Day 14 p.i., a histopathological analysis was performed. Blinded quantification of CD3-positive T cells and Mac-3-positive macrophages and microglia on spinal cord cross-sections did not reveal any difference in inflammatory infiltration between GfapF and control mice ( Table 1) . Investigation of luxol fast blue stainings revealed that the demyelinated areas in GfapF mice were not different in comparison to controls (Table 1 and Fig. 2D ). In contrast, analysis of APP immunohistochemistry showed a significant increase in APP-positive profiles in GfapF mice corroborating acute axonal damage ( Fig. 2D and E) . In parallel, axonal densities in GfapF mice were decreased in lesions, perilesions, the normal-appearing white matter and also the grey matter. These differences were not seen upon blinded quantification of axon numbers in the spinal cord white and grey matter of naive GfapF and littermate control mice ( Fig. 2D and F) .
Endogenous immune cell-derived BDNF confers axon protection in chronic MOG-EAE
To analyse the functional role of endogenous BDNF derived from immune cells during autoimmune demyelination, we generated mice with a conditional deficiency of BDNF in T cells (lckCre BDNF fl/fl mice), myeloid cells (lysMCre BDNF fl/fl mice) and a combination thereof (lysMCre lckCre BDNF fl/fl mice, designated as LLF mice). These mice bred and developed normally and did not display any spontaneous phenotype. Importantly, a reverse transcriptase polymerase chain reaction analysis did not reveal any difference in trkB expression between immune cells from LLF mice and wild-type mice (data not shown). LLF mice showed BDNF mRNA levels of 10-20% compared to wild-type T cells or wild-type peritoneal macrophages (Fig. 3A, P50 .05). In contrast, BDNF expression in the healthy brain was not altered (Fig. 3A) .
Furthermore, there was no difference in numbers of BDNF-reactive astrocytes or neurons from LLF mice and wild-type controls ( Supplementary Fig. 1A , B, D and E). To analyse the functional relevance of the reduced BDNF expression in LLF immune cells, supernatants from MOG-stimulated culture of splenocytes were tested in a dorsal root ganglion cell survival assay. In comparison to medium control, supernatants from stimulated wild-type splenocytes significantly supported neuronal survival of large calibre ganglion cells while this effect was absent using supernatants from stimulated LLF splenocytes (Fig. 3B) . To investigate whether BDNF levels were different between EAE lesions of LLF and wild-type mice, we performed western blotting and quantitative reverse transcriptase polymerase chain reaction. These analyses revealed a clear reduction of BDNF expression in LLF lesions as compared to controls (Supplementary Fig. 1G and H) . We next investigated the course of MOG-EAE in strains with a conditional BDNF deficiency in immune cells. The incidence and severity of MOG-EAE did not differ significantly between mono-conditional lckCre BDNF fl/fl or lysMCre BDNF fl/fl mice and wild-type control mice (Supplementary Fig. 2A and B) . Further experiments revealed that the clinical course of MOG-EAE in different littermate controls (BDNF fl/fl mice or lysMCre/lckCre mice)
was also similar to C57BL/6J wild-type controls, which were used in further experiments ( Supplementary Fig. 2C ). The early phase of MOG-EAE, until Day 30 p.i., was less severe in double-conditional LLF mice (Fig. 3C and data not shown, P50.001). Splenocytes from LLF mice displayed a reduced proliferative response to antigen-specific stimulation with MOG and also polyclonal stimulation with ConA, which was associated with a decreased interleukin-2 production ( Supplementary Fig. 3A and data not shown). Moreover, we observed an impaired production of the pro-inflammatory cytokines interferon-and interleukin-17 (Supplementary Fig. 3B and C) . To dissect the effects of endogenous BDNF from immune cells on axonal preservation, we investigated the late phase of MOG-EAE in LLF mice where inflammation declines, but tissue destruction increases due to incomplete repair (Herrero-Herranz et al., 2008) . In a total of four experiments, LLF and wild-type control mice were followed until Day 71 p.i. In comparison to the maximum of disease (Day 20 p.i.), wild-type mice displayed a gradual improvement of 1.5 score points over the course of disease and suffered from mild paraparesis. In contrast, LLF mice showed an incremental disability after Day 30 p.i. with an increase of over one score point and severe paraparesis until Day 71 p.i. (P = 0.0003, Fig. 3C and D) . This statistically significant effect was also evident in a separate cohort when analysing matched pairs of mice with an identical score at Day 20 p.i. and follow-up until Day 60 p.i. (Fig. 3E ). We performed a histological analysis in the chronic phase of MOG-EAE on Days 54 and 71 p.i. Upon investigation of inflammatory infiltration and myelin loss, there was significantly less infiltration of CD3-positive T cells and Mac-3-positive macrophages/microglia as well as a decreased myelin loss in LLF mice on Day 54 p.i. On Day 71 p.i., these differences were no longer detectable as myelin loss increased while inflammatory infiltration decreased (Table 2 ). There was a significant reduction of axonal densities in the lesions of LLF mice already on Day 54 p.i. (compare histopathology in Fig. 4A ) and even more on Day 71 p.i. There is a trend towards a more widespread demyelination in GfapF mice. APP staining and silver impregnation revealed a more pronounced axonal injury in GfapF mice. (E) Blinded quantification of APP-positive profiles on spinal cord cross-sections (Day 14 p.i.) reveals a significant increase in APP-positive profiles in GfapF mice (white bar, n = 8) in comparison to controls (black bar, n = 5; P = 0.034). (F) At the same time point, susceptibility to axonal loss in GfapF mice is increased. After induction of MOG-EAE, axonal densities in lesions (L), perilesional areas (PL), normal appearing white matter (NAWM) and grey matter (GM) were significantly reduced. In contrast axon numbers in naive GfapF mice were similar to controls. The mean clinical scores on the day of histological analysis were 5.5 AE 2.7 for wild-type mice versus 6.3 AE 1.8 for GfapF mice.
while axonal densities in the perilesion and the normal-appearing white matter were not changed (Fig. 4B ). In the grey matter, there was a mild, but statistically significant decrease in axonal densities only at the later time point of analysis. Axonal densities in the white and grey matter of naive LLF mice were not different from control mice (Fig. 4B) . In summary, MOG-EAE in the late phase of disease in LLF mice is characterized by a more severe disease course and increased axonal loss without enhanced inflammatory infiltration.
Glatiramer acetate-mediated axon protection is mediated via immune cell-derived BDNF
Since we found that endogenous immune cell-derived BDNF plays a crucial role for axon protection in chronic MOG-EAE, we were then interested to investigate further the therapeutic modulation of BDNF during autoimmune demyelination. At first, we analysed the therapeutic efficacy of glatiramer acetate, which is a wellestablished disease-modifying drug in multiple sclerosis and known to enhance BDNF production in human T cells in vitro and also in situ in EAE lesions. While the immunological effect of glatiramer acetate was shown to be mediated via modulation of antigen-presenting cells, it may also possess neuroprotective effects. In chronic MOG-EAE (Day 72 p.i.), glatiramer acetate treatment by co-immunization with MOG resulted in a significantly ameliorated course of disease ( Fig. 5A ) with reduced infiltration of T cells and macrophages (data not shown) and consequently also preservation of axons (Fig. 5C ). At that late time point, untreated LLF mice displayed no differences in immune cell infiltration, but reduced numbers of axons in EAE lesions ( Fig. 5C ; see also Fig. 4 ). Upon treatment of LLF mice with glatiramer acetate, the clinical efficacy of glatiramer acetate was attenuated as compared to wild-type mice (Fig. 5A) . In a blinded histological evaluation on Day 72 p.i., conditional BDNF deficiency in immune cells led to an almost complete loss of glatiramer acetate-mediated axon perseveration (Fig. 5C ). In contrast, the LLF phenotype did not influence the beneficial effects of glatiramer acetate on the reduction of immune cells in EAE lesions at the maximum of disease. In the chronic disease phase, numbers of infiltrating T cells were also not different, while there was a slightly higher number of infiltrating macrophages and activated microglia in glatiramer acetate-treated LLF mice ( Fig. 5B and Table 3 ).
In summary, these data argue for glatiramer acetatemediated axon protection that involves BDNF expression in immune cells.
Exogenous BDNF mediates axonal protection in MOG-EAE
We were finally interested to study the therapeutic relevance of immune cell-derived BDNF in a setting without modulation of the immune response. To this end, a lentiviral complementation approach was used to target exogenous BDNF to inflamed EAE lesions. Infection of human embryonic kidney cells with a lentiviral vector encoding BDNF resulted in a significant production of BDNF protein (data not shown) showing the integrity of the construct. Bioactivity of the lentivirally produced BDNF was proven in a survival assay upon application of human embryonic kidney cell culture supernatants on murine dorsal root ganglion cells (Fig. 6A ). In the next step, a MOG-specific T-cell line was infected with this BDNF-encoding lentivirus. The characterization of these cells by reverse transcriptase polymerase chain reaction revealed an over 60-fold increase in BDNF expression as compared to uninfected cells (Fig. 6B) . To ensure homing of T cells into EAE lesions and at the same time allowing the tracking of cells in vivo, infections in further experiments were performed with green fluorescent protein expressing T cells harbouring a transgenic T-cell receptor recognizing the MOG 35-55 epitope (Bettelli et al., 2003) . These green MOG-specific BDNF overexpressing T cells were injected into C57BL/6 recipients on Day 7 after immunization with MOG 35-55, a time point after completion of T-cell priming and shortly before the first clinical symptoms occur (Day 11 p.i.). In a next step, we aimed to prove the functional relevance of overexpressed BDNF from MOG-specific T cells in EAE lesions in situ. To this end, we performed double-labelling experiments for immune cells and phosphor-TrkB where the phosphorylated form indicates binding of BDNF to its receptor. Indeed, injection of BDNF overexpressing MOG-specific T-cell receptor transgenic T cells resulted in a more widespread activation of phospho TrkB in and around EAE lesions that are characterized by infiltration of T cells and macrophages (Fig. 6C) .
Upon investigation of the clinical course, a single injection of the BDNF overexpressing T cells led to a significantly milder MOG-EAE in comparison to mice injected with T cells infected with a green fluorescent protein virus as control (Fig. 6D) . Tracking of green fluorescent protein-positive cells by fluorescence-activated cell-sorting analyses proved homing also into inflamed EAE lesions and revealed that green fluorescent protein-positive T cells harvested from the inflamed spinal cord did not express higher levels of the activation marker CD25 while CD44 was rather decreased (Fig. 6E and F) , thus identifying BDNF-overexpressing cells as a bystander component in the inflammatory infiltrate. Similar results were obtained upon analyses of splenocytes (data not shown). In a histopathological analysis, numbers of infiltrating CD3-positive 8.4 AE 0.9 5.9 AE 0.7 6/7 0.04 13.3 AE 3.3 13.1 AE 2.8 5/7 n.s.
Blinded quantification of CD3-positive T cells, Mac-3-positive macrophages/microglia and myelin loss after luxol fast blue staining reveals a reduced inflammatory infiltration as well as myelin loss on Day 54 p.i. These differences were no longer present on Day 71 p.i. LLF mice were analysed in comparison to wild-type mice. CD3-positive and Mac-3-positive cells are shown as cells/mm 2 ; numbers of mice and P-values are indicated. n.s. indicates P40.05.
T cells and Mac-3-positive macrophages/microglia as well as demyelinated areas after luxol fast blue or CNPase staining on Day 22 p.i. did not differ between mice treated with BDNF-overexpressing T cells and controls (Table 4 and Fig. 6G ). At this time point, staining for APP and inducible nitric oxide synthase disclosed a trend to decreased APP-positive profiles and inducible nitric oxide synthase-positive phagocytes in mice treated with BDNF-overexpressing T cells (89 AE 16 APP-positive profiles after injection BDNF-overexpressing T cells versus 139 AE 25 profiles in the control group and data not shown). Blinded quantification of silver-stained axons revealed a significant protection of axons with an increase in axonal densities in lesions. Axonal densities in the perilesional area were also significantly preserved while axon numbers in the normal-appearing white matter and also in the grey matter were not different from control mice ( Fig. 6H and histopathology Fig. 6G ). Furthermore, using confocal laser scanning microscopy after staining for neurofilament and CNPase, we could show that injection of BDNF-overexpressing T cells led to preservation of naked, intact axons containing phosphorylated, SMI31-positive axons in EAE lesions. In contrast, numbers of damaged, non-phosphorylated and SMI32-positive axons were clearly reduced (Fig. 6I) . In summary, targeting of exogenous BDNF to EAE lesions via lentiviral infection of MOG-specific T cells results in axon protective effects without altering the immune response.
Discussion
Our findings are indicative of a protective role of endogenous BDNF in the chronically inflamed nervous system that can be therapeutically modulated.
First, endogenous BDNF from immune cells plays a neuroprotective role during MOG-EAE. Despite a less severe clinical course in the early phase of MOG-EAE in LLF mice due to a weakened inflammatory assault, the lack of endogenous immune cell-derived BDNF leads to impaired neuroprotection and eventually enhanced axonal loss in the chronic disease phase. This observation and, as a consequence, the more severe disease course of MOG-EAE in the late phase argue in favour of the concept of neuroprotective autoimmunity in autoimmune demyelination (Hohlfeld et al., 2000; Schwartz et al., 2001 ) and identify BDNF as a possible molecular basis of this hypothesis. Indeed, an axon protective role of BDNF in EAE is well in line with previous studies describing effects of BDNF on axon survival in different lesion paradigms (Markus et al., 2002) and neurodegenerative diseases (Canals et al., 2004) . Furthermore, the results from GfapF mice strongly support the functional relevance of BDNF as a major axon protective factor. This effect is mainly carried out directly at the level of axon preservation that is corroborated by our finding that naked axons in EAE lesions express phosphorylated TrkB indicative of direct BDNF binding to its high-affinity receptor. In contrast, direct effects on myelination were not observed, as suggested in models of spinal cord injury (McTigue et al., 1998; Hohlfeld et al., 2000; Ikeda et al., 2002) . The trend towards an enhanced myelin loss, particularly in GfapF mice, may be rather explained by loss of myelin secondary to loss of axons. Interestingly, LLF mice showed (n = 4 mice per group). The mean clinical scores were 0.9 AE 0.9 (for WT + GA), 3.1 AE 1.2 (LLF + GA), 5.1 AE 0.6 (wild-type control) and 5.6 AE 0.7 (LLF control). While glatiramer acetate treatment leads to a significant preservation of axons in EAE lesions of wild-type mice, axonal densities in glatiramer acetate-treated LLF mice are reduced to a degree as in untreated wild-type mice.
an enhanced axonal loss only in lesions while GfapF mice displayed an overall increased axonal loss also in the normal-appearing white and grey matter. This discrepancy may be explained by the paracrine action of BDNF, which in LLF mice is only lacking in lesions with infiltrates of immune cells. In contrast, conditional knockout mice using the glial fibrillary acidic protein promoter and therefore displaying gene recombination in astrocytes as well as some neuronal subpopulations have the phenotype of a more generalized reduction of BDNF levels in the CNS. The overall increased axonal loss in these mice is in line with the observation of decreased axonal densities not only in lesions but also in white and grey matter early during the course of MOG-EAE (Herrero-Herranz et al., 2008) . The observed reduction of BDNF expression in the diseased spinal cord may best be explained by an early axonal loss in the lesions, resulting in not only a secondary loss of myelin but also loss of trophic factors normally provided by intact neurons.
Second, another level of evidence is provided by the supplementation of exogenous BDNF to the lesion area, which enhances axon protection in autoimmune demyelination without influencing the immune response. There are preliminary reports on the successful therapeutic application of BNDF in mouse models of motor neuron degeneration (Mitsumoto et al., 1994) . However, therapeutic trials with BDNF in human motor neuron disease failed (The BDNF Study Group, 1999) , possibly due to limited bioavailability of BDNF in the CNS (Dittrich et al., 1996) . Exogenous administration of free BDNF was also inefficient in a model of experimental autoimmune neuritis (Felts et al., 2002) . We thus chose to deliver BDNF via lentiviral transduction of MOG-specific T cells. In our model, treatment with these cells was initiated at Day 7 p.i., when axonal loss becomes apparent in EAE lesions (Herrero-Herranz et al., 2008; Jones et al., 2008) , but after completion of the initial T-cell priming. Thus, the supplemented MOG-specific T cells home into EAE lesions, but remain quiescent (Kramer et al., 1995; Bettelli et al., 2003) . In contrast, application of BDNF at earlier time points may also result in impaired immune responses as shown after application of BDNF-transformed bone marrow stem cells in EAE (Makar et al., 2008 (Makar et al., , 2009 ). The assumed half-life of BDNF-overexpressing T cells in EAE lesions is about 1 week after which they undergo apoptosis and are cleared from the CNS, thus necessitating repeated injections for a sustained effect over time that limits the feasibility of therapeutic application in long-term experiments.
Third, endogenous BDNF in immune cells influence the therapeutic efficacy of glatiramer acetate. While glatiramer acetate reduces inflammatory infiltration and leads to axonal preservation in wild-type mice, its effects on axons require BDNF expression by immune cells. Thus, our data support a dual action of glatiramer acetate in autoimmune demyelination that involves BDNFdependent protective effects on axons on the one hand and modulatory effects on immune cells on the other (Kipnis et al., 2002) . Effects of glatiramer acetate on immune cells may include a Th2 shift (Neuhaus et al., 2000) , an increase in regulatory T cells (Tennakoon et al., 2006) and most importantly, a modulation of antigen presenting cells, especially monocytes (Weber et al., 2007) . Neuroprotective actions of glatiramer acetate and glatiramer acetate-specific T cells have been described in primary degenerative models of amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease (Angelov et al., 2003; Avidan et al., 2004; Reynolds et al., 2007) and also in inflammatory diseases including HIV encephalitis and optic neuritis (Maier et al., 2006; Gorantla et al., 2007) . In the setting of neurodegeneration, glatiramer acetate may directly mediate effects on neurons or also induce neurogenesis and act via neurotrophic factors (Aharoni et al., 2005) . Our data functionally link axonoprotective effects of glatiramer acetate in autoimmune demyelination to BDNF production by immune cells. This observation is well in line with descriptive reports on the induction of BDNF expression in immune cells in vitro and in EAE lesions after glatiramer acetate treatment (Ziemssen et al., 2002; Aharoni et al., 2003) .
In summary, the enhanced susceptibility to axonal loss in conditional BDNF knockout mice and the axonal preservation after T-cell-mediated targeting of exogenous BDNF to EAE lesions provide evidence for the functional relevance of the concept of neuroprotective autoimmunity. These data place BDNF into the focus of interest as a potential therapeutic target in autoimmune demyelination of the CNS. 
